bioxcell產(chǎn)品--recombimab anti-mouse ctla-4 (cd152)
產(chǎn)品描述：
9d9-cp006單克隆抗體是原始9d9單克隆抗體的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始9d9克隆號(hào)相同，但是恒定區(qū)序列已經(jīng)從小鼠igg2b變?yōu)樾∈骾gg1。9d9-cp006單克隆抗體能與小鼠ctla-4(細(xì)胞毒性t淋巴細(xì)胞抗原-4)反應(yīng)，ctla-4也稱為cd152。ctla-4是一種33 kda的細(xì)胞表面受體，由屬于免疫球蛋白超家族cd28家族的ctla4基因編碼。ctla-4在活化的t淋巴細(xì)胞和b淋巴細(xì)胞上表達(dá)。ctla-4在結(jié)構(gòu)上類似于t細(xì)胞共刺激蛋白cd28，兩種分子都與b7家族成員b7-1 (cd80)和b7-2 (cd86)結(jié)合。在與配體結(jié)合時(shí)，ctla-4負(fù)調(diào)節(jié)細(xì)胞介導(dǎo)的免疫反應(yīng)。ctla-4在誘導(dǎo)和/或維持免疫耐受、胸腺細(xì)胞發(fā)育和保護(hù)性免疫調(diào)節(jié)中起作用。ctla-4在免疫下調(diào)中的關(guān)鍵作用已經(jīng)在ctla-4缺陷小鼠中得到證實(shí)，這些小鼠在3-5周齡時(shí)由于淋巴增生性疾病的發(fā)展而死亡。ctla-4是目前腫瘤免疫檢查點(diǎn)治療的熱門靶點(diǎn)之一。
產(chǎn)品詳情：
產(chǎn)品名稱
recombimab anti-mouse ctla-4 (cd152)
產(chǎn)品貨號(hào)
cp006
產(chǎn)品規(guī)格
1mg
反應(yīng)種屬
mouse
克隆號(hào)
9d9-cp006
同種型
mouse igg1(switched from mouse igg2b)
免疫原
not available or unknown
實(shí)驗(yàn)應(yīng)用
in vivo ctla-4 neutralization*
western blot*
*reported for the original mouse igg2b 9d9 antibody
產(chǎn)品形式
pbs, ph 7.0,contains no stabilizers or preservatives
純度
>95%, determined by sds-page
聚合
<5%, determined by sec
無菌處理
0.2 µm filtration
純化方式
protein g
分子量
150 kda
小鼠病原檢測(cè)
ectromelia/mousepox virus: negative
hantavirus: negative
k virus: negative
lactate dehydrogenase-elevating virus: negative
lymphocytic choriomeningitis virus: negative
mouse adenovirus: negative
mouse cytomegalovirus: negative
mouse hepatitis virus: negative
mouse minute virus: negative
mouse norovirus: negative
mouse parvovirus: negative
mouse rotavirus: negative
mycoplasma pulmonis: negative
pneumonia virus of mice: negative
polyoma virus: negative
reovirus screen: negative
sendai virus: negative
theiler’s murine encephalomyelitis: negative
保存條件
抗體原液保存在4°c，不能冷凍保存。
推薦同型對(duì)照
invivoplus mouse igg1 isotype control, unknown specificity（貨號(hào)bp0083）
推薦抗體稀釋液
invivopure ph 7.0 dilution buffer（貨號(hào)ip0070）
該產(chǎn)品自上市已被多篇sci文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
應(yīng)用
文章
體內(nèi)ctla-4中和
(in vivo ctla-4
neutralization)
1.dai, m., et al. (2015). 'curing mice with large tumors by locally delivering
combinations of immunomodulatory antibodies' clin cancer res 21(5): 1127-1138.
2.zippelius, a., et al. (2015). 'induced pd-l1 expression mediates acquired
resistance to agonistic anti-cd40 treatment' cancer immunol res 3(3): 236-244.
3.redmond, w. l., et al. (2014). 'combined targeting of costimulatory (ox40)
and coinhibitory (ctla-4) pathways elicits potent effector t cells capable of
driving robust antitumor immunity' cancer immunol res 2(2): 142-153.
4.condamine, t., et al. (2014). 'er stress regulates myeloid-derived suppressor
cell fate through trail-r-mediated apoptosis' j clin invest 124(6): 2626-2639.
5.muller, p., et al. (2014). 'microtubule-depolymerizing agents used in antibody-drug
conjugates induce antitumor immunity by stimulation of dendritic cells' cancer immunol
res 2(8): 741-755.
6.bulliard, y., et al. (2013). 'activating fc gamma receptors contribute to the antitumor
activities of immunoregulatory receptor-targeting antibodies' j exp med 210(9): 1685-1693.
更多產(chǎn)品詳情請(qǐng)聯(lián)系 bioxcell 中國(guó)授權(quán)代理——欣博盛生物